Clinical trial
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple…
NCT00078338 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00078338 |
|---|---|
| Title | Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis |
| Official title | Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis |
| Lead sponsor | EMD Serono, Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Relapsing-remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Rebif®, Copaxone® |
| Enrollment | 764 |
| Start date | Feb 16, 2004 |
| Primary completion | Nov 28, 2006 |
| Completion | Nov 28, 2006 |
| First posted | Feb 26, 2004 |
| Last update posted | Jun 27, 2018 |
| Countries | Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russia, Spain, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: